Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
基本信息
- 批准号:7129242
- 负责人:
- 金额:$ 40.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): All responsible governments are greatly concerned about the possibility that the highly lethal H5N1 influenza A viruses that have been killing large numbers of wild and domestic birds (and a few people) in South East Asia may suddenly change their host range and begin to spread globally, with extreme rapidity, among human populations. Though we have an effective anti-influenza drug (Oseltamivir), a new-generation H5N1 vaccine is in an advanced stage of development, and the influenza virus research, surveillance and public health networks are first class, the capacity of these viruses to mutate very rapidly means that there is no way to be absolutely sure that we will not be hit by a virus against which we relatively little protection. The current formalin-inactivated vaccines promote a highly specific and effective antibody response, provided this is directed against exactly the right virus, but they do not stimulate the more cross-reactive cell-mediated immunity (CMI) that can give some measure of protection against a broad spectrum of influenza A viruses. The question is, should we be thinking about vaccine strategies that also induce virus-specific CD4+ and CD8+ "memory" T cells, in the knowledge that the more rapid emergence of these effectors of CMI will, at best, ameliorate the severity of the disease rather than prevent infection completely? Though it is the case that many people will already have some influenza-specific T cell memory, it is also likely that regular boosting will greatly increase both the numbers of these memory T cells and the rapidity of the recall response following live virus challenge. The present experiments address the effectiveness and characteristics of the CMI response in mice that have (like people) previously been exposed to heterologous influenza A viruses, then infected with these highly virulent H5N1 influenza A viruses. A variety of genetically engineered and reassortant viruses will be used in prime, boost and challenge experiments to investigate the limits of protection and the cellular mechanisms that might be selectively promoted if an effective CMI- directed vaccine were to be developed. Whether the H5N1 viruses have particular characteristics that tend to subvert the protection conferred by pre-existing CMI will also be addressed, in the hope of identifying strategies that might be used to defeat such effects. These studies should allow us to develop a clear, mechanistic understanding of how to promote effective CMI against the H5N1 viruses.
描述(由申请人提供):所有负责任的政府都非常担心在东南亚造成大量野生和家禽(以及少数人)死亡的高致命性H5N1甲型流感病毒可能突然改变其宿主范围,并开始在全球人群中以极快的速度传播。虽然我们有一种有效的抗流感药物(奥司他韦),新一代H5N1疫苗正处于开发的后期阶段,流感病毒的研究、监测和公共卫生网络是一流的,但这些病毒非常迅速地变异的能力意味着,我们没有办法绝对肯定我们不会受到一种我们相对缺乏保护的病毒的袭击。目前的福尔马林灭活疫苗促进了高度特异性和有效的抗体反应,前提是这种反应是针对正确的病毒,但它们不能刺激更具交叉反应性的细胞介导免疫(CMI),而这种免疫可以对广谱甲型流感病毒提供一定程度的保护。问题是,我们是否应该考虑疫苗策略,也诱导病毒特异性CD4+和CD8+“记忆”T细胞,在认识到这些CMI效应物的更快出现,最多只能减轻疾病的严重程度,而不是完全预防感染?尽管许多人已经拥有一些流感特异性T细胞记忆,但也有可能定期增强将大大增加这些记忆T细胞的数量,并在活病毒攻击后迅速召回反应。本实验探讨了小鼠(像人一样)先前暴露于异源甲型流感病毒,然后感染这些高毒力H5N1甲型流感病毒的CMI反应的有效性和特征。多种基因工程和重组病毒将用于启动、增强和挑战实验,以研究如果开发出有效的CMI定向疫苗,可能选择性促进的保护限度和细胞机制。还将讨论H5N1病毒是否具有倾向于破坏预先存在的CMI所赋予的保护的特殊特征,以期确定可能用于挫败此类影响的策略。这些研究应使我们能够对如何促进有效的CMI对抗H5N1病毒有一个清晰的、机械的认识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER C DOHERTY其他文献
PETER C DOHERTY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER C DOHERTY', 18)}}的其他基金
Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
- 批准号:
7426908 - 财政年份:2006
- 资助金额:
$ 40.46万 - 项目类别:
Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
- 批准号:
7849033 - 财政年份:2006
- 资助金额:
$ 40.46万 - 项目类别:
Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
- 批准号:
7232680 - 财政年份:2006
- 资助金额:
$ 40.46万 - 项目类别:
Protective Cell-Mediated Immunity Against Lethal H5N1 Influenza A Viruses
针对致命性 H5N1 甲型流感病毒的保护性细胞介导的免疫
- 批准号:
7622169 - 财政年份:2006
- 资助金额:
$ 40.46万 - 项目类别:
SINGLE CELL ANALYSIS OF A MULTI-TIER AIDS VACCINE
多层艾滋病疫苗的单细胞分析
- 批准号:
6320775 - 财政年份:2000
- 资助金额:
$ 40.46万 - 项目类别:
SINGLE CELL ANALYSIS OF A MULTI-TIER AIDS VACCINE
多层艾滋病疫苗的单细胞分析
- 批准号:
6167468 - 财政年份:1999
- 资助金额:
$ 40.46万 - 项目类别:
相似国自然基金
基于健康行为改变整合理论的艾滋病感染者自我管理生态圈网络系统构建与初步应用
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
肠道菌群介导的脱氧胆酸激活S1PR2/NLRP3/IL-1β通路在炎症性肠病合并艰难梭菌感染中的致病机制研究
- 批准号:82372306
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
牙周炎对腹主动脉瘤的作用和机制研究
- 批准号:82370953
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
基于质谱贴片的病原菌标志物检测及伤口感染诊断应用
- 批准号:82372148
- 批准年份:2023
- 资助金额:60.00 万元
- 项目类别:面上项目
DNA糖苷酶OGG1调节PARP1介导的EB病毒潜伏蛋白表达的机制研究
- 批准号:32000546
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
结核分枝杆菌感染巨噬细胞后自噬相关LncRNA分子的筛选及其调控机制研究
- 批准号:31760326
- 批准年份:2017
- 资助金额:36.0 万元
- 项目类别:地区科学基金项目
基于反式互补的新型丙型肝炎病毒细胞感染模型的建立及其在丙肝研究中的应用
- 批准号:31170149
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
microRNA对机体抗病毒固有免疫应答RIG-I信号途径的调控作用及机制研究
- 批准号:31170826
- 批准年份:2011
- 资助金额:70.0 万元
- 项目类别:面上项目
丙型肝炎病毒感染宿主细胞的分子生物学研究
- 批准号:30870127
- 批准年份:2008
- 资助金额:40.0 万元
- 项目类别:面上项目
相似海外基金
Syudy on highly pathogenic avian influenza infection in innate immunity
Syudy 论高致病性禽流感感染的先天免疫
- 批准号:
23H02364 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Application of New Tools for Probing the Roles of Sphingolipids and Cholesterol in Influenza Virus Infection
应用新工具探索鞘脂和胆固醇在流感病毒感染中的作用
- 批准号:
10678459 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
The Impact of SARS-CoV-2 Immune Dysregulation on Antifungal Immunity
SARS-CoV-2 免疫失调对抗真菌免疫的影响
- 批准号:
10658355 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Mechanisms of antiviral immunity and tolerance in the intestinal epithelium of Jamaican Fruit Bats
牙买加果蝠肠上皮的抗病毒免疫和耐受机制
- 批准号:
10592671 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Democratizing CAR T cell therapy by in situ programming of virus-specific T cells
通过病毒特异性 T 细胞的原位编程使 CAR T 细胞疗法大众化
- 批准号:
10739646 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Sex-specific effects of obestity on Influenza A virus infection and immunity
肥胖对甲型流感病毒感染和免疫力的性别特异性影响
- 批准号:
10915128 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Therapeutically harnessing anti-viral resident memory T cells in solid tumors
利用抗病毒驻留记忆 T 细胞治疗实体瘤
- 批准号:
10586695 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Antiviral innate immune responses to pathogenic coronaviruses in the nasal epithelium
鼻上皮中针对致病性冠状病毒的抗病毒先天免疫反应
- 批准号:
10678393 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Characterization of seasonal CoV immunity and operationalization of a novel controlled human infection model for the betacoronavirus OC43
β冠状病毒 OC43 的季节性 CoV 免疫特征和新型受控人类感染模型的操作
- 批准号:
10663727 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别:
Targeting IKK-alpha in lymphatics to drive protective tertiary lymphoid organ formation
靶向淋巴管中的 IKK-α 来驱动保护性三级淋巴器官的形成
- 批准号:
10667005 - 财政年份:2023
- 资助金额:
$ 40.46万 - 项目类别: